- Home
- SNN vs KYMR Comparison
SNN vs KYMR Comparison
Compare SNN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNN | KYMR |
|---|---|---|
| Founded | 1856 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.6B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNN | KYMR |
|---|---|---|
| Price | $29.15 | $120.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 26 |
| Target Price | $36.25 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 1.3M | 640.5K |
| Earning Date | 03-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $8.58 | $10.61 |
| Revenue Next Year | $5.60 | $8.17 |
| P/E Ratio | $64.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.56 | $39.84 |
| 52 Week High | $38.79 | $130.05 |
Technical Indicators
Market Signals| Indicator | SNN | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 57.55 |
| Support Level | $28.56 | $76.40 |
| Resistance Level | $30.52 | $130.05 |
| Average True Range (ATR) | 0.39 | 4.82 |
| MACD | -0.08 | 0.58 |
| Stochastic Oscillator | 28.99 | 68.37 |
Price Performance
Historical ComparisonAbout SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.